Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome

NCT01205087 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG: OKT3

Sponsor

Hadassah Medical Organization

Collaborators

[object Object]